ArticleDermatology and therapy2019

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.

Makoto Shiragami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.